BioSpace News Archive

The Company also summarized recent program updates and reiterated full-year 2017 financial guidance.

H.C. Wainwright & Co., LLC is acting as the sole book-running manager for the offering.

Science Exchange announced today that ReproCELL has selected the Science Exchange platform as the primary marketplace to offer access to its predictive drug discovery assays for the biopharma research community.

Voyager has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock at the public offering price.

Cash, cash equivalents and marketable securities as of September 30, 2017 were $81.9 million, compared with $83.6 million on December 31, 2016.

Ignyta today announced new preclinical data for RXDX-106 - a novel immunomodulatory agent that demonstrated potent anti-tumor activity, alone and in combination with checkpoint inhibitors, by modulating the tumor microenvironment (TME) through TYRO3, AXL, and MER (TAM) receptor tyrosine kinase (RTK) inhibition.

This designation is given to a few select medical devices in order to provide more effective treatment of life-threatening or irreversibly debilitating diseases or conditions.

GraviFeed and Guardian Warmer have both received a 2017 Innovative Technology designation from Vizient, the largest member-driven health care performance improvement company in the country.

Tepha announced today recent developments and R & D initiatives in the field of regenerative medicine scaffolds for the repair or replacement of compromised human tissue.

In this role, Dr. Brown will lead all functions in the company’s R&D organization, including research and discovery, clinical development and exploration of Dendreon’s therapeutic platform for other oncology indications.